Antibody-Drug Conjugates

Jul 15, 2026

For most of medical history, treating disease meant casting a wide net. Chemotherapy attacked every fast-dividing cell it could find, healthy or cancerous. Broad-spectrum drugs treated symptoms without ever asking why a particular patient's biology behaved the way it did. That era is ending. Targeted therapeutics, ...

Jul 07, 2026

Novartis to Acquire Myricx Bio to Expand Next-Generation ADC Portfolio Novartis has signed an agreement to acquire Myricx Bio, a privately owned biotechnology company based in the UK that is developing a novel class of antibody-drug conjugates (ADCs) featuring N-myristoyltransferase inhibitor (NMTi) payloads. ...

Jun 12, 2026

Pfizer's USD 10.5 billion partnership with Innovent Biologics is not just another oncology deal; it is a strategic masterstroke in Pfizer's bid to dominate cancer therapy. In May 2026, Pfizer and Innovent announced a global collaboration covering 12 early-stage and de novo oncology programs, including next-generati...

Jan 02, 2026

Delta-like Ligand 3 (DLL3) is rapidly establishing a position as one of the promising targets in the treatment of aggressive Neuroendocrine Cancers (NECs), including Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Cancer (NEPC), and Large-Cell Neuroendocrine Carcinoma (LCNEC), where existing treatments deliv...

Dec 05, 2025

Glypican-3 (GPC3) has emerged as one of the most promising therapeutic targets in oncology, particularly in hepatocellular carcinoma and select solid tumors. As a cell surface heparan sulfate proteoglycan that is overexpressed in approximately 75% of hepatocellular carcinoma cases while remaining virtually absent i...

Jul 15, 2025

Nanoscope Therapeutics Begins FDA Rolling Submission for MCO-010 in Retinitis Pigmentosa Nanoscope Therapeutics has initiated a rolling submission of its Biologics License Application (BLA) to the FDA for MCO-010, a first-in-class, gene-agnostic optogenetic therapy targeting severe vision loss due to retinitis p...

May 09, 2025

Lung cancer remains the leading cause of cancer-related death in the United States; approximately 85% of lung cancers are non-small cell lung cancer (NSCLC), with ~530K cases in the 7MM. The main subtypes of NSCLC are adenocarcinoma (~57%), squamous cell carcinoma (~26%), and large cell carcinoma (~2%). Despite adv...

Mar 07, 2025

On March 3, 2025, BeiGene secured another approval for its anti-PD-1 antibody, TEVIMBRA, as the FDA granted clearance for its use in combination with platinum-based chemotherapy as a first-line treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1....

Oct 04, 2024

Trispecific antibodies are the next frontier in targeted cancer therapy, offering a powerful new approach to treating complex diseases. These innovative antibodies are designed to bind to three different antigens simultaneously, enhancing treatment precision. By engaging multiple targets at once, trispecific antibo...

Jun 02, 2023

Antibody-drug conjugates (ADCs) are becoming more prominent in the cancer treatment market. Antibody-drug conjugates are one of the most rapidly increasing anticancer treatments. This approach uses a mAb attached to a cytotoxic payload via a chemical linker that is directed towards a target antigen expressed on the...